Skip to main content
BHSTNasdaq

BIOHARVEST SCIENCES INC.

·Vancouver, BC, Canada·CEO: Dr. Zaki Rakib Ph.D.

BHST evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for BHST—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

BioSniper AI · BHST

BioHarvest Sciences Inc. (BHST) is a biotechnology company based in Vancouver, Canada, focused on developing and commercializing botanical-based products. As of its latest financial report (2025-12-31), the company reported $34.5M in revenue and a net loss of $11.1M.

Key risk: Negative net income

2.2/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

$41.7M

Cash Runway

10.5 mo

Lead Asset

Next Catalyst

Financial data as of Dec 31, 2025.

AI OverviewAI overview is shown in English only.

BioHarvest Sciences Inc. (BHST) is a biotechnology company based in Vancouver, Canada, focused on developing and commercializing botanical-based products. As of its latest financial report (2025-12-31), the company reported $34.5M in revenue and a net loss of $11.1M.

  • Cash and equivalents of $23.0M as of 2025-12-31 [sec].
  • Total revenue of $34.5M for the period ending 2025-12-31 [sec].
  • Net loss of $11.1M for the period ending 2025-12-31 [sec].
  • Shareholders' equity of $1.3M as of 2025-12-31 [sec].
  • Total debt of $10.3M as of 2025-12-31 [sec].

What works

  • Revenue generation of $34.5M indicates commercial activity and market presence [sec].
  • Cash position of $23.0M provides a liquidity buffer for operations and development [sec].

What to weigh

  • Net loss of $11.1M reflects ongoing operational expenses exceeding revenue [sec].
  • Shareholders' equity of $1.3M is low relative to total debt of $10.3M, indicating a leveraged balance sheet [sec].
Risks & what to watch (2)

Key risks

  • Negative net incomeThe company reported a net loss of $11.1M as of 2025-12-31, indicating ongoing unprofitability [sec].
  • High debt relative to equityTotal debt of $10.3M exceeds shareholders' equity of $1.3M as of 2025-12-31, suggesting financial leverage risk [sec].

What to watch

  • Future revenue growth and path to profitability [sec].
  • Ability to manage debt and improve equity position [sec].
  • Any new product developments or regulatory milestones [sec].

Sources: SEC filings · Generated August 25, 2026 · How we verify sources →

Run BIOHARVEST SCIENCES INC. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available BIOHARVEST SCIENCES INC. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Evidence & data

Score breakdownBased on 2 of 6 signals · derived from public data

No clinical pipeline tracked — this score reflects financial & catalyst signals only.

Cash Runway2.9

10.5 months

Financial Health1.5

OCF -$7M · Net income -$11M

Pipeline MaturityN/A

No tracked pipeline phase

Pipeline BreadthN/A

No tracked pipeline candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Financials

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

15

Total value held

$3.9M

Showing top 10 of 15 institutional holders of BIOHARVEST SCIENCES INC.. Open the full 13F history after sign-in.

Short Interest

as of May 20, 2026
% of float
0.3%
Days to cover
2.2
Shares short
64,823
Daily short volume (Aug 4, 2026)
8.4%

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

BHST short interest

Frequently asked questions

What is the AI investment thesis for BIOHARVEST SCIENCES INC.?

BioHarvest Sciences Inc. (BHST) is a biotechnology company based in Vancouver, Canada, focused on developing and commercializing botanical-based products. As of its latest financial report (2025-12-31), the company reported $34.5M in revenue and a net loss of $11.1M.

Who is the CEO of BIOHARVEST SCIENCES INC.?

Dr. Zaki Rakib Ph.D. is the chief executive officer of BIOHARVEST SCIENCES INC. (BHST).

Where is BIOHARVEST SCIENCES INC. headquartered?

BIOHARVEST SCIENCES INC. (BHST) is headquartered in Vancouver, BC, Canada.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.